First CNSide payer agreement to include CNSide’s new CSF Molecular Profile tests alongside tumor cell enumerationExpands CNSide contracted payer ...
Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today highlighted ...
ABL Texcell Diagnostics (Euronext Paris: ABLD – ISIN: FR001400AHX6) (the "Company"), a company specializing in molecular diagnostic solutions, healthcare software and services supporting clinical ...
(Nasdaq: CNSY) (“Cerenome” or the “Company ”), today announced the commercial launch of two new cerebrospinal fluid (CSF)-based molecular profiling tests, available to health care professionals in the ...
2don MSN
Motilal Oswal initiates coverage on Molbio Diagnostics stock with buy, sees 21% upside. Here's why
Motilal Oswal initiated coverage on Molbio Diagnostics with a Buy rating and ₹1,800 target, implying 21% upside. The brokerage sees strong growth potential from decentralised molecular diagnostics, ...
Title: "High-Throughput Enteric Testing: Advancing Speed, Scale, and Stewardship" Inside Molecular: Conversations Across BD Molecular Diagnostics is a podcast series exploring the BD Molecular ...
New automation platform brings open, AI-assisted automation to molecular microbiology and NGS workflows, with configurations from €50,000 to €90,000 WOIPPY, FRANCE, October 5, 2026 /EINPresswire.com/ ...
Point-of-care molecular diagnostics are gaining traction, reducing costs, improving outcomes and combating antimicrobial resistance, with potential to replace frontline testing protocols.Dublin, Sept.
Roche Diagnostics has provided two molecular testing instruments to the Institut National de Santé Publique (INSP), which is supporting the DRC's Ministry of Health-led Ebola response. Roche will ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results